FDA approves bevacizumab biosimilar Jobevne

Biosimilars/News | Posted 22/05/2025 comments 0
Bevacizumab 1 V14f01

On 9 April 2025, the US Food and Drug Administration (FDA) has approved Biocon’s Jobevne (bevacizumab-nwgd), a biosimilar bevacizumab referencing Roche’s Avastin, for intravenous (IV) use.

More >
FORO LATINOAMERICANO DE ESTA SEMANA
Optional Mandatory V19C01
Advances in EMA plans to streamline biosimilar assessment
Posted 07/04/2025

On 1 April 2025, the European Medicines Agency (EMA) published a ‘draft reflection pape...

Turkey 2016 COVER V16E31DG
Biosimilars in low- and middle-income countries
Posted 05/03/2025

Biosimilars offer a viable route to treatment for those with non-communicable diseases...

Clinical trial PainSA V21F04
Comparative efficacy studies: where are we now?
Posted 08/01/2025

In an article published in GaBI Journal titled ‘Comparative efficac...

Home/Non‐Biological Complex Drugs
Liposome V15L11

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidance...

More >